{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T12:49:33Z","timestamp":1793191773232,"version":"4.5.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:00:00Z","timestamp":1750723200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.jtha.2025.06.013","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T14:47:55Z","timestamp":1750171675000},"page":"3098-3110","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["A first-in-human study of NXT007, a next-generation, activated factor VIII-mimetic bispecific antibody, in healthy participants"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6730-7873","authenticated-orcid":false,"given":"Takehiko","family":"Sambe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9181-1604","authenticated-orcid":false,"given":"Takuya","family":"Miwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8166-6522","authenticated-orcid":false,"given":"Koichiro","family":"Yoneyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4053-7096","authenticated-orcid":false,"given":"Takaaki","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7066-9315","authenticated-orcid":false,"given":"Taigi","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5922-7061","authenticated-orcid":false,"given":"Midori","family":"Shima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2025.06.013_bib1","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0140-6736(15)01123-X","article-title":"The past and future of haemophilia: diagnosis, treatments, and its complications","volume":"388","author":"Peyvandi","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2025.06.013_bib2","series-title":"WFH guidelines for the management of hemophilia","first-page":"1","article-title":"WFH Guidelines for the Management of Hemophilia panelists and co-authors","volume":"26","author":"Srivastava","year":"2020"},{"key":"10.1016\/j.jtha.2025.06.013_bib3","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/hae.14958","article-title":"Defining success in haemophilia care - are we doing it right?","volume":"30","author":"Srivastava","year":"2024","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.06.013_bib4","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/hae.15002","article-title":"The good, the bad and the ugly of pain in haemophilia: recent evidence on the epidemiology, molecular mechanisms and knowledge gaps preventing optimal treatment","volume":"30","author":"Benemei","year":"2024","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.06.013_bib5","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/hae.14201","article-title":"Clinical phenotype of severe and moderate haemophilia: who should receive prophylaxis and what is the target trough level?","volume":"27","author":"Collins","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.06.013_bib7","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.hoc.2019.01.007","article-title":"Hemophilia in a changing treatment landscape","volume":"33","author":"Pelland\u2013Marcotte","year":"2019","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.jtha.2025.06.013_bib8","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.2147\/JBM.S260923","article-title":"Clinical utility of subcutaneous factor VIII replacement therapies in hemophilia A: a review of the evidence","volume":"12","author":"Dargaud","year":"2021","journal-title":"J Blood Med"},{"key":"10.1016\/j.jtha.2025.06.013_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2023.101164","article-title":"Nothing short of a revolution: novel extended half-life factor VIII replacement products and non-replacement agents reshape the treatment landscape in hemophilia A","volume":"64","author":"Abdelgawad","year":"2024","journal-title":"Blood Rev"},{"key":"10.1016\/j.jtha.2025.06.013_bib10","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1080\/17474086.2023.2223925","article-title":"Efanesoctocog alfa for the prevention and treatment of bleeding in patients with hemophilia A","volume":"16","author":"Konkle","year":"2023","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.jtha.2025.06.013_bib11","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2209226","article-title":"Efanesoctocog alfa prophylaxis for patients with severe hemophilia A","volume":"388","author":"von Drygalski","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.06.013_bib12","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/hae.14982","article-title":"Haemophilia in the era of novel therapies: where do inhibitors feature in the new landscape?","volume":"30","author":"Meeks","year":"2024","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.06.013_bib13","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.1182\/blood-2012-09-457036","article-title":"Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study","volume":"121","author":"Gouw","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.06.013_bib14","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1046\/j.1365-2516.2003.00780.x","article-title":"The epidemiology of inhibitors in haemophilia A: a systematic review","volume":"9","author":"Wight","year":"2003","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.06.013_bib15","doi-asserted-by":"crossref","first-page":"6367","DOI":"10.1182\/blood-2010-09-308668","article-title":"Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom","volume":"117","author":"Hay","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.06.013_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0057479","article-title":"Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity","volume":"8","author":"Sampei","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jtha.2025.06.013_bib17","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1160\/TH17-01-0030","article-title":"Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX\/IXa and X\/Xa, emicizumab, depends on its ability to bridge the antigens","volume":"117","author":"Kitazawa","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.013_bib18","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1182\/blood-2015-06-650226","article-title":"A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects","volume":"127","author":"Uchida","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.06.013_bib19","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/cpdd.617","article-title":"Relative and absolute bioavailability study of emicizumab to bridge drug products and subcutaneous injection sites in healthy volunteers","volume":"8","author":"Kotani","year":"2019","journal-title":"Clin Pharmacol Drug Devel"},{"key":"10.1016\/j.jtha.2025.06.013_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2024.102415","article-title":"Emicizumab is well tolerated and effective in people with congenital hemophilia A regardless of age, severity of disease, or inhibitor status: a scoping review","volume":"8","author":"Young","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.013_bib21","article-title":"Prophylactic emicizumab for hemophilia A in the Asia-Pacific region: a randomized study (HAVEN 5)","volume":"6","author":"Yang","year":"2022","journal-title":"Res Pract Thromb Haemostast"},{"key":"10.1016\/j.jtha.2025.06.013_bib22","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12837","article-title":"Safety and efficacy of long-term emicizumab prophylaxis in hemophilia A with factor VIII inhibitors: a phase 3b, multicenter, single-arm study (STASEY)","volume":"6","author":"Jim\u00e9nez\u2013Yuste","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.013_bib23","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/hae.13848","article-title":"A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors","volume":"25","author":"Shima","year":"2019","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.06.013_bib24","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1182\/blood.2023021832","article-title":"Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b, open-label trial","volume":"143","author":"Pipe","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.06.013_bib25","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1016\/S2352-3026(22)00377-5","article-title":"Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study","volume":"10","author":"N\u00e9grier","year":"2023","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtha.2025.06.013_bib26","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.06.013_bib27","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood.2019001869","article-title":"A multicenter, open-label, phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors","volume":"134","author":"Young","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.06.013_bib28","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients with hemophilia A without inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.06.013_bib29","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1016\/S2352-3026(19)30054-7","article-title":"Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study","volume":"6","author":"Pipe","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtha.2025.06.013_bib30","doi-asserted-by":"crossref","first-page":"e698","DOI":"10.1111\/hae.14432","article-title":"Real-world experience on the tolerability and safety of emicizumab prophylaxis in paediatric patients with severe haemophilia A with and without FVIII inhibitors","volume":"27","author":"Hassan","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.06.013_bib31","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2020-138918","article-title":"Real-world clinical outcomes in previously untreated and minimally treated patients with congenital factor VIII deficiency: the San Diego experience","volume":"136","author":"Bush","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.06.013_bib32","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/hae.14318","article-title":"Emicizumab prophylaxis: prospective longitudinal real-world follow-up and monitoring","volume":"27","author":"Barg","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.06.013_bib33","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/hae.14261","article-title":"Emicizumab prophylaxis in haemophilia patients older than 50 years with cardiovascular risk factors: real-world data","volume":"27","author":"Misgav","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.06.013_bib34","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1080\/17512433.2023.2243213","article-title":"Clinical pharmacology of emicizumab for the treatment of hemophilia A","volume":"16","author":"Yoneyama","year":"2023","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.jtha.2025.06.013_bib35","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1111\/bjh.14543","article-title":"Treatment burden, haemostatic strategies and real world inhibitor screening practice in non-severe haemophilia A","volume":"176","author":"Batty","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2025.06.013_bib37","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1111\/hae.14866","article-title":"Targeting higher factor VIII levels for prophylaxis in haemophilia A: a narrative review","volume":"29","author":"Malec","year":"2023","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.06.013_bib38","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMoa2216455","article-title":"Phase 3 trial of concizumab in hemophilia with inhibitors","volume":"389","author":"Matsushita","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.06.013_bib39","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/bjh.18495","article-title":"Long-term safety and efficacy of the anti-tissue factor pathway inhibitor marstacimab in participants with severe haemophilia: phase II study results","volume":"200","author":"Mahlangu","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2025.06.013_bib40","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(23)00284-2","article-title":"Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial","volume":"401","author":"Young","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2025.06.013_bib41","doi-asserted-by":"crossref","first-page":"e322","DOI":"10.1016\/S2352-3026(23)00037-6","article-title":"Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A\/B): a multicentre, open-label, randomised, phase 3 trial","volume":"10","author":"Srivastava","year":"2023","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtha.2025.06.013_bib42","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.jtha.2023.12.016","article-title":"FRONTIER1: a partially randomized phase 2 study assessing the safety, pharmacokinetics, and pharmacodynamics of Mim8, a factor VIIIa mimetic","volume":"22","author":"Lentz","year":"2024","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.013_bib43","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2222441","article-title":"Efficient production of bispecific antibody by FAST-Ig(TM) and its application to NXT007 for the treatment of hemophilia A","volume":"15","author":"Koga","year":"2023","journal-title":"mAbs"},{"key":"10.1016\/j.jtha.2025.06.013_bib44","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.jtha.2023.09.034","article-title":"A bispecific antibody NXT007 exerts a hemostatic activity in hemophilia A monkeys enough to keep a nonhemophilic state","volume":"22","author":"Teranishi\u2013Ikawa","year":"2024","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.013_bib45","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1080\/19420862.2017.1314873","article-title":"Identification of human IgG1 variant with enhanced FcRn binding and without increased binding to rheumatoid factor autoantibody","volume":"9","author":"Maeda","year":"2017","journal-title":"mAbs"},{"key":"10.1016\/j.jtha.2025.06.013_bib46","doi-asserted-by":"crossref","first-page":"11295","DOI":"10.1182\/blood-2022-155918","article-title":"Quantitative estimation of the in vivo equivalent factor VIII activity of NXT007, an emicizumab-based, next-generation, activated factor VIII-mimetic bispecific antibody, from nonclinical data","volume":"140","author":"Yoneyama","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.06.013_bib49","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1208\/s12248-014-9599-2","article-title":"American Association of Pharmaceutical Scientists. Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations","volume":"16","author":"Shankar","year":"2014","journal-title":"AAPS J"},{"key":"10.1016\/j.jtha.2025.06.013_bib50","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/hae.14398","article-title":"Low immunogenicity of emicizumab in persons with haemophilia A","volume":"27","author":"Schmitt","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.06.013_bib51","doi-asserted-by":"crossref","first-page":"3190","DOI":"10.1182\/blood-2021-144549","article-title":"A healthy volunteer-derived, factor VIII-neutralized, acquired hemophilia A-mimetic plasma produces similar pharmacodynamic responses of emicizumab to those in patients with congenital hemophilia A with or without inhibitors","volume":"138","author":"Yoneyama","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.06.013_bib52","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1111\/jth.14207","article-title":"A first-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-06741086, an antitissue factor pathway inhibitor mAb, in healthy volunteers","volume":"16","author":"Cardinal","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.013_bib53","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/jth.12864","article-title":"Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial","volume":"13","author":"Chowdary","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.013_bib54","article-title":"Mim8, a novel factor VIIIa mimetic bispecific antibody, shows favorable safety and pharmacokinetics in healthy adults","volume":"7","author":"Persson","year":"2023","journal-title":"Res Prac Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.013_bib55","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood-2023-181263","article-title":"Efficacy and safety of the antitissue factor pathway inhibitor marstacimab in participants with severe hemophilia without inhibitors: results from the phase 3 basis trial","volume":"142","author":"Matino","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.06.013_bib56","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abq5858","article-title":"A long-acting anti-IL-8 antibody improves inflammation and fibrosis in endometriosis","volume":"15","author":"Nishimoto\u2013Kakiuchi","year":"2023","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jtha.2025.06.013_bib57","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009262","article-title":"Phase I study of the safety and clinical activity of the interleukin-8 inhibitor AMY109 combined with atezolizumab in patients with advanced solid cancers","volume":"12","author":"Yamamoto","year":"2024","journal-title":"J Immunotherap Cancer"},{"key":"10.1016\/j.jtha.2025.06.013_bib58","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1038\/s41598-017-01087-7","article-title":"Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases","volume":"7","author":"Fukuzawa","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtha.2025.06.013_bib59","first-page":"4750","article-title":"The SMART-IgG Anti-hC5 antibody (SKY59\/RO7112689) has favorable PK, PD, subcutaneous bioavailability, and safety profile in phase I HV study","volume":"130","author":"Roeth","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.06.013_bib60","series-title":"PIASKY (crovalimab-akkz) injection for intravenous or subcutaneous use","year":"2024"},{"key":"10.1016\/j.jtha.2025.06.013_bib61","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/cpt.3573","article-title":"IQ survey results on current industry practices: part 2-quantitative evaluations of immunogenicity assessment","volume":"117","author":"Richards","year":"2025","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jtha.2025.06.013_bib62","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s40262-012-0027-4","article-title":"Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies","volume":"52","author":"Dostalek","year":"2013","journal-title":"Clin Pharmacokinet"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153878362500399X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153878362500399X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T05:29:06Z","timestamp":1758950946000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S153878362500399X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":58,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S153878362500399X"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2025.06.013","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A first-in-human study of NXT007, a next-generation, activated factor VIII-mimetic bispecific antibody, in healthy participants","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2025.06.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}